Weekly · monthly · quarterly news summaries, side by side in time
No Positive Developments The period contained no positive news for GeneDx. The only constructive note is that the legal process has defined timelines, but resolution remains distant, leaving investors with little to cheer.
It underscores the absence of catalysts and the persistent negative sentiment.
No Positive Developments The period contained no positive news for GeneDx. The only constructive note is that the legal process has defined timelines, but resolution remains distant, leaving investors with little to cheer.
It underscores the absence of catalysts and the persistent negative sentiment.
August 3 lead plaintiff deadline keeps lawsuit in focus Investors have until August 3, 2026 to ask to lead the securities fraud class action over the Fabric Genomics deal. The deadline keeps the allegations in the news and stretches out uncertainty, which tends to hold the stock down until the matter is resolved.
This is the only new development this period — the deadline is approaching and multiple firms are reminding investors, which keeps the legal overhang active.
Law firms keep pressing the Fabric Genomics fraud case Multiple law firms are now investigating or reminding investors about the securities fraud class action tied to the Fabric Genomics deal. Each new firm joining keeps the legal cloud over GeneDx, and the threat of penalties and damaged management credibility weighs on the stock.
Shows the legal pressure is broadening, not fading, which is the main new force on WGS.
August 3 deadline keeps the lawsuit in the spotlight Investors have until August 3, 2026 to ask to lead the case. That date keeps the allegations in the news and stretches out the uncertainty, which tends to hold the stock down until the matter is resolved.
The approaching deadline is a concrete new event that keeps negative attention on the stock.
The $31.2 million write-off is the heart of the case The lawsuits center on the Fabric Genomics purchase, which GeneDx wrote down by $31.2 million — nearly all the cash it paid a year earlier. That failed deal, plus a 12% guidance cut, is what triggered the 49% stock collapse.
Explains the underlying business failure that all the new legal stories are built on.
Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.
This is the main new event of the period and directly explains negative pressure on WGS.
Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.
The deadline is a new concrete development that sustains negative attention on WGS.
CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.
This is a new insider transaction that may affect investor sentiment.
Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.
This is the main new event of the period and directly explains negative pressure on WGS.
Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.
The deadline is a new concrete development that sustains negative attention on WGS.
CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.
This is a new insider transaction that may affect investor sentiment.
Securities fraud class action filed A securities fraud class action alleges GeneDx misled investors about the Fabric Genomics acquisition. The lawsuit creates legal uncertainty and potential financial penalties, weighing on WGS shares as investors worry about liability and management credibility.
This is the main new event of the period and directly explains negative pressure on WGS.
Lead plaintiff deadline set for August 3 Investors have until August 3, 2026, to seek lead plaintiff status in the class action. The deadline keeps the lawsuit in the spotlight, reminding the market of the allegations and prolonging uncertainty that can hold the stock down.
The deadline is a new concrete development that sustains negative attention on WGS.
CFO sells shares to cover taxes GeneDx's CFO sold $227,000 in stock on June 16 to cover tax obligations from vesting restricted shares. While not a discretionary sale, it can still unsettle investors by signaling insider selling, adding mild downward pressure.
This is a new insider transaction that may affect investor sentiment.
Record Q2 sales and raised guidance Abbott reported record second-quarter sales of $12.6 billion, beat expectations, and raised its earnings guidance. Diagnostics grew 42.3% and Medical Devices grew 9%, showing broad strength across the business.
This is the core financial result that drove positive sentiment in the period.
New product approvals and partnerships FDA approved Freenome's colorectal cancer blood test, Abbott partnered with Google Health for Lingo, and won approvals for diabetes and heart devices like Libre Duo and Amulet 360. These expand future revenue streams.
These pipeline advances strengthen Abbott's long-term growth prospects.
Legal clouds ease with settlements Abbott partly settled NEC claims for $670 million and infant-formula claims for $385 million. This reduces legal uncertainty, though about 1,700 NEC lawsuits remain outstanding.
Legal settlements remove overhangs that had pressured the stock.
$21B Exact Sciences deal dilutes guidance Abbott's $21 billion acquisition of Exact Sciences diluted earnings guidance and increased interest expense. While it may boost long-term growth, the near-term financial impact weighed on the stock.
This is the main negative factor that offset positive developments.
FDA clears first dual glucose-ketone sensor Abbott won FDA authorization for Libre Duo 10 Day, the first biowearable that tracks both glucose and ketones, with a U.S. launch planned for later this year. A genuinely new product with no direct rival strengthens Abbott's fast-growing diabetes sensor business and supports a higher stock price.
A first-of-its-kind product approval is a real new growth driver, not a repeat of earlier news.
Two new heart-device approvals widen Abbott's lead Abbott received CE Mark for the Amulet 360 stroke-prevention device and FDA approval for the TactiFlex Duo ablation catheter, its fourth and fifth heart-rhythm approvals in about a year. More approved tools mean more procedures and recurring sales, pushing the stock up.
These are new regulatory wins that expand Abbott's electrophysiology lineup and revenue runway.
Infant formula legal overhang largely resolved Abbott agreed to pay $385 million to settle Department of Justice and state claims over its 2022 Sturgis formula recall, with no finding of fault and the criminal probe closed. Removing this legal cloud lets investors focus on the core business, lifting the stock.
This is a new settlement that clears a major legal risk, a direct positive for the share price.
Citi sees Abbott taking heart-device share from Boston Scientific Citi downgraded rival Boston Scientific, saying it will lose market share in left atrial appendage closure when Abbott's Amulet device launches in 2027. That independent view of Abbott as the winner in a growing market supports the stock.
A fresh analyst call frames Abbott as a competitive gainer, a new reason for optimism.
FDA clears first dual glucose-ketone sensor Abbott won FDA authorization for Libre Duo 10 Day, the first biowearable that tracks both glucose and ketones, with a U.S. launch planned for later this year. A genuinely new product with no direct rival strengthens Abbott's fast-growing diabetes sensor business and supports a higher stock price.
A first-of-its-kind product approval is a real new growth driver, not a repeat of earlier news.
Two new heart-device approvals widen Abbott's lead Abbott received CE Mark for the Amulet 360 stroke-prevention device and FDA approval for the TactiFlex Duo ablation catheter, its fourth and fifth heart-rhythm approvals in about a year. More approved tools mean more procedures and recurring sales, pushing the stock up.
These are new regulatory wins that expand Abbott's electrophysiology lineup and revenue runway.
Infant formula legal overhang largely resolved Abbott agreed to pay $385 million to settle Department of Justice and state claims over its 2022 Sturgis formula recall, with no finding of fault and the criminal probe closed. Removing this legal cloud lets investors focus on the core business, lifting the stock.
This is a new settlement that clears a major legal risk, a direct positive for the share price.
Citi sees Abbott taking heart-device share from Boston Scientific Citi downgraded rival Boston Scientific, saying it will lose market share in left atrial appendage closure when Abbott's Amulet device launches in 2027. That independent view of Abbott as the winner in a growing market supports the stock.
A fresh analyst call frames Abbott as a competitive gainer, a new reason for optimism.
Google Health partnership expands Lingo reach Abbott and Google launched a multi-year partnership to embed Lingo glucose data into the Google Health app, pairing it with AI coaching. This could drive adoption of Abbott's biowearable and open a new consumer health channel, supporting the stock.
New partnership is a fresh growth catalyst for Abbott's diabetes care business.
Instinct sensor powers MiniMed's new insulin pump Abbott is supplying its Instinct sensor for MiniMed's app-controlled insulin pump in the U.S. This broadens Abbott's role in diabetes devices and adds recurring sensor revenue, a positive for the stock.
New product integration expands Abbott's diabetes device footprint.
Medical devices growth driven by electrophysiology and CGM Abbott's medical devices arm is accelerating, with the Volt PFA catheter launching fully and CGM adoption far below its 75-80 million potential users. This long runway supports future revenue growth and a higher stock price.
Highlights durable growth drivers in Abbott's largest device segments.
NEC litigation settled for $670 million, but 1,700 cases remain Abbott agreed to pay about $670 million to settle the Gill case and roughly 2,000 NEC claims, without admitting liability. While this removes a major overhang, about 1,700 lawsuits remain, keeping some legal uncertainty on the stock.
Settlement is a major legal development that reduces but does not eliminate litigation risk.
Google Health partnership expands Lingo reach Abbott and Google launched a multi-year partnership to embed Lingo glucose data into the Google Health app, pairing it with AI coaching. This could drive adoption of Abbott's biowearable and open a new consumer health channel, supporting the stock.
New partnership is a fresh growth catalyst for Abbott's diabetes care business.
Instinct sensor powers MiniMed's new insulin pump Abbott is supplying its Instinct sensor for MiniMed's app-controlled insulin pump in the U.S. This broadens Abbott's role in diabetes devices and adds recurring sensor revenue, a positive for the stock.
New product integration expands Abbott's diabetes device footprint.
Medical devices growth driven by electrophysiology and CGM Abbott's medical devices arm is accelerating, with the Volt PFA catheter launching fully and CGM adoption far below its 75-80 million potential users. This long runway supports future revenue growth and a higher stock price.
Highlights durable growth drivers in Abbott's largest device segments.
NEC litigation settled for $670 million, but 1,700 cases remain Abbott agreed to pay about $670 million to settle the Gill case and roughly 2,000 NEC claims, without admitting liability. While this removes a major overhang, about 1,700 lawsuits remain, keeping some legal uncertainty on the stock.
Settlement is a major legal development that reduces but does not eliminate litigation risk.
Q2 earnings beat and raised guidance Abbott reported record Q2 sales of $12.6 billion, up 13%, and adjusted EPS of $1.31, beating expectations. Management raised full-year EPS guidance to $5.45–$5.60, sending the stock up over 10% initially.
This is the main new event that drove the stock in July.
Medical Devices and Diagnostics growth Medical Devices grew 9%, while Diagnostics surged 42.3% due to the Exact Sciences acquisition. Nutrition trends also improved, showing broad-based strength across Abbott's businesses.
These segment results explain the strong revenue beat and support the positive reaction.
FDA approval of Freenome CRC blood test The FDA approved Freenome's colorectal cancer blood test, which Abbott will exclusively commercialize in the U.S. This adds a new revenue stream and expands Abbott's diagnostic offerings.
This is a new product approval that could drive future growth.
Exact Sciences costs and NEC litigation The $21 billion Exact Sciences deal diluted guidance and spiked interest expense from $50 million to $299 million. Ongoing NEC litigation uncertainty continues to weigh on investor sentiment, keeping a lid on the stock.
These are the main counterweights that prevented even stronger gains.
Q2 beat and raised guidance Abbott reported record Q2 sales of $12.6 billion, up 13%, and adjusted EPS of $1.31, beating estimates. Management raised full-year adjusted EPS guidance to $5.45–$5.60. This shows the core business is strong and supports a higher stock price.
This is the main positive driver this period, directly boosting investor confidence and the stock's valuation.
FDA approves Freenome CRC blood test, Abbott to commercialize The FDA approved Freenome's SimpleScreen CRC blood test, and Abbott will exclusively sell it in the U.S. starting this fall. This expands Abbott's cancer diagnostics portfolio and adds a new revenue stream, pushing the stock up.
This is a new product approval that directly expands Abbott's diagnostics business and future sales.
Exact Sciences acquisition dilutes guidance and raises interest expense Abbott's $21 billion Exact Sciences acquisition added $919 million in Cologuard sales but also caused interest expense to jump from $50 million to $299 million and diluted full-year guidance. This weighs on the stock as investors worry about the cost of the deal.
This is a key counterweight explaining why the stock hasn't risen more despite strong results.
Ongoing NEC litigation uncertainty Uncertainty around NEC litigation related to Abbott's preterm infant formula continues to weigh on investor sentiment. This legal risk keeps a lid on the stock price, as investors await clarity on potential liabilities.
This is a persistent negative factor that offsets positive business momentum.
Q2 beat and raised full-year guidance Abbott reported Q2 adjusted EPS of $1.31, beating estimates, with sales up 13% to $12.59 billion. Management raised full-year adjusted EPS guidance to $5.45–$5.60 and reaffirmed comparable sales growth of 6.5–7.5%. The stock jumped over 10% as results eased worries about medical devices and nutrition.
This is the main new event that directly drove the stock's sharp move this period.
Medical Devices and Diagnostics strength Medical Devices sales grew 9% to $5.85 billion, led by electrophysiology and diabetes care. Diagnostics surged 42.3% to $3.09 billion after the Exact Sciences acquisition, with cancer diagnostics growing double digits. This shows the core businesses are performing well and supports future growth.
It explains which parts of the business are driving the beat and future optimism.
Nutrition and other segments improving Nutrition sales declined 3.1% but rose sequentially by $125 million, and management expects about 80% of the second-half lift from Nutrition, Electrophysiology, Core Laboratory, and Cancer Diagnostics. Established Pharmaceuticals grew 8.4%. This signals a turnaround in previously weak areas.
It shows the company is addressing prior weaknesses, which supports the raised guidance.
DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.
DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.
DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.